The stock of Halozyme Therapeutics Inc. (NASDAQ: HALO) has decreased by -0.55 when compared to last closing price of 38.02.Despite this, the company has seen
Halozyme Therapeutics Inc. (NASDAQ: HALO) has a price-to-earnings ratio that is above its average at 18.62x. The stock has a 36-month beta value of 1.26.
The stock of Halozyme Therapeutics Inc. (HALO) has gone down by -2.46% for the week, with a -4.06% drop in the past month and a
Halozyme Therapeutics Inc. (NASDAQ: HALO) has experienced a decline in its stock price by -0.40 compared to its previous closing price of 40.38. However, the
© 2024, Fueled by Smart TechOne
